SEC Form 4 · accession 0001231919-26-001194

Tyra Biosciences, Inc. · TYRA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

Director · 10% Owner

Director · 10% Owner

Director · 10% Owner

Director · 10% Owner

Director

Period of report

Sep 15, 2026

Accepted (ET)

Sep 17, 2026 · 4:31 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001863127

Table I — non-derivative securities

No Table I lines on this filing.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Pre-Funded Warrants (Right to Buy)^F2,F3,F1	$0.001	Sep 15, 2026	P	9,078,529	A	—	—	Common Stock	9,078,529	11,616,986	I

F1The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrants to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 19.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.
F2RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F3Held directly by the Fund.

Jake Simson, a Partner of the Adviser, serves on the Issuer's board of directors.